Concepción Pérez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Concepción Pérez has a total of 83 co-authors. Here are the top co-authors by number of shared publications:
- Nuria Eugenia Campillo
Centro de Investigaciones Biológicas Margarita Salas (CIB Margarita Salas−CSIC)
4 shared publications - Ana Martinez
Centro de Investigaciones Biologicas, CSIC Madrid Spain
2 shared publications - Carmen Gil
Translational Medicinal and Biological Chemistry Group, Margarita Salas Center of Biological Research, CIB-CSIC, Ramiro de Maeztu 9, 28040, Madrid, Spain
2 shared publications Concepción Pérez
Instituto de Quimica Medica (CSIC), Juan de la Cierva 3, 28006 Madrid, Spain
2 shared publications- Juan Antonio Páez
Instituto de Quimica Medica (CSIC), Juan de la Cierva 3, 28006 Madrid, Spain
2 shared publications A García Gancedo
1 shared publication
Latest Publications
- Open Access
- 21 February 2025
- Published by American Chemical Society (ACS) in ChemRxiv
AI-driven de-novo design and development of non-toxic DYRK1A inhibitors
(DYRK1A) plays a key role in various diseases, including DYRK1A syndrome, cancer, diabetes, and neurodegenerative disorders such as Alzheimer’s disease (AD), making it a compelling therapeutic target. This work integrates multiple Artificial Intelligence (AI) methods, including predictive models and generative algorithms, to design non-toxic DYRK1A inhibitors. A dual-target drug discovery framework is constructed by combining AI-driven approaches with classical techniques. An ensemble Quantitative Structure-Activity Relationship (QSAR) model predicts compound affinities, while Directed Message Passing Neural Networks (DMPNN) assess toxicity. In the generative phase, a Hierarchical Graph Generation (HGG) model facilitates the design of potential inhibitors, which are further refined through docking studies, synthesized, and experimentally validated. This approach led to the identification of the pyrazolyl-1H-pyrrolo[2,3-b]pyridine 1 as a potent DYRK1A inhibitor, prompting the synthesis of a novel derivative series. Enzymatic assays confirmed nanomolar-level inhibitory activity, while ORAC assays and LPS-induced pro-inflammatory response evaluations in BV2 microglial cells demonstrated antioxidant and anti-inflammatory properties. Overall, these compounds exhibit strong DYRK1A inhibition alongside promising pharmacological effects.
- 21 February 2025
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessAI-driven de-novo design and development of non-toxic DYRK1A inhibitors
(DYRK1A) plays a key role in various diseases, including DYRK1A syndrome, cancer, diabetes, and neurodegenerative disorders such as Alzheimer’s disease (AD), making it a compelling therapeutic target. This work integrates multiple Artificial Intelligence (AI) methods, including predictive models and generative algorithms, to design non-toxic DYRK1A inhibitors. A dual-target drug discovery framework is constructed by combining AI-driven approaches with classical techniques. An ensemble Quantitative Structure-Activity Relationship (QSAR) model predicts compound affinities, while Directed Message Passing Neural Networks (DMPNN) assess toxicity. In the generative phase, a Hierarchical Graph Generation (HGG) model facilitates the design of potential inhibitors, which are further refined through docking studies, synthesized, and experimentally validated. This approach led to the identification of the pyrazolyl-1H-pyrrolo[2,3-b]pyridine 1 as a potent DYRK1A inhibitor, prompting the synthesis of a novel derivative series. Enzymatic assays confirmed nanomolar-level inhibitory activity, while ORAC assays and LPS-induced pro-inflammatory response evaluations in BV2 microglial cells demonstrated antioxidant and anti-inflammatory properties. Overall, these compounds exhibit strong DYRK1A inhibition alongside promising pharmacological effects.
- Open Access
- 1 September 2022
- Published by Taylor & Francis in Journal of Enzyme Inhibition and Medicinal Chemistry
- Vol. 37 (1) , 2348-2356
Multitarget drugs as potential therapeutic agents for alzheimer’s disease. A new family of 5-substituted indazole derivatives as cholinergic and BACE1 inhibitors
Multitarget drugs are a promising therapeutic approach against Alzheimer’s disease. In this work, a new family of 5-substituted indazole derivatives with a multitarget profile including cholinesterase and BACE1 inhibition is described. Thus, the synthesis and evaluation of a new class of 5-substituted indazoles has been performed. Pharmacological evaluation includes in vitro inhibitory assays on AChE/BuChE and BACE1 enzymes. Also, the corresponding competition studies on BuChE were carried out. Additionally, antioxidant properties have been calculated from ORAC assays. Furthermore, studies of anti-inflammatory properties on Raw 264.7 cells and neuroprotective effects in human neuroblastoma SH-SY5Y cells have been performed. The results of pharmacological tests have shown that some of these 5-substituted indazole derivatives 1–4 and 6 behave as AChE/BuChE and BACE1 inhibitors, simultaneously. In addition, some indazole derivatives showed anti-inflammatory (3, 6) and neuroprotective (1–4 and 6) effects against Aβ-induced cell death in human neuroblastoma SH-SY5Y cells with antioxidant properties.
- 1 September 2022
- Published by Taylor & Francis in Journal of Enzyme Inhibition and Medicinal Chemistry
- Vol. 37 (1) , 2348-2356
Open AccessMultitarget drugs as potential therapeutic agents for alzheimer’s disease. A new family of 5-substituted indazole derivatives as cholinergic and BACE1 inhibitors
Multitarget drugs are a promising therapeutic approach against Alzheimer’s disease. In this work, a new family of 5-substituted indazole derivatives with a multitarget profile including cholinesterase and BACE1 inhibition is described. Thus, the synthesis and evaluation of a new class of 5-substituted indazoles has been performed. Pharmacological evaluation includes in vitro inhibitory assays on AChE/BuChE and BACE1 enzymes. Also, the corresponding competition studies on BuChE were carried out. Additionally, antioxidant properties have been calculated from ORAC assays. Furthermore, studies of anti-inflammatory properties on Raw 264.7 cells and neuroprotective effects in human neuroblastoma SH-SY5Y cells have been performed. The results of pharmacological tests have shown that some of these 5-substituted indazole derivatives 1–4 and 6 behave as AChE/BuChE and BACE1 inhibitors, simultaneously. In addition, some indazole derivatives showed anti-inflammatory (3, 6) and neuroprotective (1–4 and 6) effects against Aβ-induced cell death in human neuroblastoma SH-SY5Y cells with antioxidant properties.
- Open Access
- 14 May 2022
- Published by MDPI AG in Biomedicines
- Vol. 10 (5) , 1136
Naphthoquinone as a New Chemical Scaffold for Leishmanicidal Inhibitors of Leishmania GSK-3
More than 1 billion people live in areas endemic for leishmaniasis, which is a relevant threat for public health worldwide. Due to the inadequate treatments, there is an urgent need to develop novel alternative drugs and to validate new targets to fight this disease. One appealing approach is the selective inhibition of protein kinases (PKs), enzymes involved in a wide range of processes along the life cycle of Leishmania. Several PKs, including glycogen synthase kinase 3 (GSK-3), have been validated as essential for this parasite by genetic or pharmacological methods. Recently, novel chemical scaffolds have been uncovered as Leishmania GSK-3 inhibitors with antiparasitic activity. In order to find new inhibitors of this enzyme, a virtual screening of our in-house chemical library was carried out on the structure of the Leishmania GSK-3. The virtual hits identified were experimentally assayed both for leishmanicidal activity and for in vitro inhibition of the enzyme. The best hits have a quinone scaffold. Their optimization through a medicinal chemistry approach led to a set of new compounds, provided a frame to establish biochemical and antiparasitic structure–activity relationships, and delivered molecules with an improved selectivity index. Altogether, this study paves the way for a systemic search of this class of inhibitors for further development as potential leishmanicidal drugs.
- 14 May 2022
- Published by MDPI AG in Biomedicines
- Vol. 10 (5) , 1136
Open AccessNaphthoquinone as a New Chemical Scaffold for Leishmanicidal Inhibitors of Leishmania GSK-3
More than 1 billion people live in areas endemic for leishmaniasis, which is a relevant threat for public health worldwide. Due to the inadequate treatments, there is an urgent need to develop novel alternative drugs and to validate new targets to fight this disease. One appealing approach is the selective inhibition of protein kinases (PKs), enzymes involved in a wide range of processes along the life cycle of Leishmania. Several PKs, including glycogen synthase kinase 3 (GSK-3), have been validated as essential for this parasite by genetic or pharmacological methods. Recently, novel chemical scaffolds have been uncovered as Leishmania GSK-3 inhibitors with antiparasitic activity. In order to find new inhibitors of this enzyme, a virtual screening of our in-house chemical library was carried out on the structure of the Leishmania GSK-3. The virtual hits identified were experimentally assayed both for leishmanicidal activity and for in vitro inhibition of the enzyme. The best hits have a quinone scaffold. Their optimization through a medicinal chemistry approach led to a set of new compounds, provided a frame to establish biochemical and antiparasitic structure–activity relationships, and delivered molecules with an improved selectivity index. Altogether, this study paves the way for a systemic search of this class of inhibitors for further development as potential leishmanicidal drugs.
- 1 April 2021
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 216, 113331
Developing novel classes of protein kinase CK1δ inhibitors by fusing [1,2,4]triazole with different bicyclic heteroaromatic systems
- 1 April 2021
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 216, 113331
Developing novel classes of protein kinase CK1δ inhibitors by fusing [1,2,4]triazole with different bicyclic heteroaromatic systems
- 1 January 2021
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 210, 112968
Targeting nuclear protein TDP-43 by cell division cycle kinase 7 inhibitors: A new therapeutic approach for amyotrophic lateral sclerosis
- 1 January 2021
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 210, 112968
Targeting nuclear protein TDP-43 by cell division cycle kinase 7 inhibitors: A new therapeutic approach for amyotrophic lateral sclerosis
- 1 February 2014
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 73, 56-72
Cannabinoid agonists showing BuChE inhibition as potential therapeutic agents for Alzheimer's disease
- 1 February 2014
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 73, 56-72
Cannabinoid agonists showing BuChE inhibition as potential therapeutic agents for Alzheimer's disease
- 17 February 2004
- Published by American Chemical Society (ACS) in Biochemistry
- Vol. 43 (10) , 2888-2897
Quinones Facilitate the Self-Assembly of the Phosphorylated Tubulin Binding Region of Tau into Fibrillar Polymers
The fragment of tau containing the first and third tubulin-binding motifs, involved in self-assembly of tau, was phosphorylated by protein kinase A (PKA). In the presence of hydroxynonenal (HNE) or in the presence of quinones such as juglone, 2,3-dimethoxy-5-methyl-1,4-benzoquinone (coenzyme Q0 or DMM), or menadione, the polymerization of this phosphorylated tau fragment is catalyzed, whereas polymerization of the unmodified fragment takes place in a lesser extent. The quinones coenzyme Q0 and menadione are found in every cell, including neural cells, and may interact with tau protein to facilitate its assembly into filamentous structures. These tau filaments, assembled in the presence of quinones, have a fibrillar morphology very similar to that of paired helical filaments present in the brains of patients with Alzheimer's disease.
- 17 February 2004
- Published by American Chemical Society (ACS) in Biochemistry
- Vol. 43 (10) , 2888-2897
Quinones Facilitate the Self-Assembly of the Phosphorylated Tubulin Binding Region of Tau into Fibrillar Polymers
The fragment of tau containing the first and third tubulin-binding motifs, involved in self-assembly of tau, was phosphorylated by protein kinase A (PKA). In the presence of hydroxynonenal (HNE) or in the presence of quinones such as juglone, 2,3-dimethoxy-5-methyl-1,4-benzoquinone (coenzyme Q0 or DMM), or menadione, the polymerization of this phosphorylated tau fragment is catalyzed, whereas polymerization of the unmodified fragment takes place in a lesser extent. The quinones coenzyme Q0 and menadione are found in every cell, including neural cells, and may interact with tau protein to facilitate its assembly into filamentous structures. These tau filaments, assembled in the presence of quinones, have a fibrillar morphology very similar to that of paired helical filaments present in the brains of patients with Alzheimer's disease.
- 1 January 1992
- Published by Wiley in Archiv der Pharmazie
- Vol. 325 (5) , 261-265
Ketomethylene Analogues of Phosphoryl Dipeptides Related to Phosphoramidon: Synthesis and Inhibition of Proteases
- 1 January 1992
- Published by Wiley in Archiv der Pharmazie
- Vol. 325 (5) , 261-265
Ketomethylene Analogues of Phosphoryl Dipeptides Related to Phosphoramidon: Synthesis and Inhibition of Proteases
- 1 March 1991
- Vol. 41 (3) , 264-6
Synthesis and biological screening of aminothiadiazine dioxides related to trimethoprim.
New derivatives of 3-amino-1,2,6-thiadiazine 1,1-dioxide have been synthesized and their antibacterial, antifungal and DHFR inhibitory activities evaluated. Their chemical structures have been established by means of analytical and NMR spectroscopic data. Among the compounds studied, the 4,4-dibromo derivative 11 showed fungistatic activity against C. albicans.
- 1 March 1991
- Vol. 41 (3) , 264-6
Synthesis and biological screening of aminothiadiazine dioxides related to trimethoprim.
New derivatives of 3-amino-1,2,6-thiadiazine 1,1-dioxide have been synthesized and their antibacterial, antifungal and DHFR inhibitory activities evaluated. Their chemical structures have been established by means of analytical and NMR spectroscopic data. Among the compounds studied, the 4,4-dibromo derivative 11 showed fungistatic activity against C. albicans.